Patents Assigned to AnaBios Corporation
  • Patent number: 10955409
    Abstract: The present invention provides methods of identifying and distinguishing different types of nerve cells in ex vivo cell culture, the method comprising the steps of: a) culturing somato-sensory nerve cells ex vivo, b) loading the nerve cells with a calcium, sodium, or voltage-sensitive indicator or expressing a genetically encoded calcium, sodium, or voltage-sensitive indicator, c) pulsing the nerve cells with an electrical train of bipolar square waves at two different voltages and two different frequencies; wherein the first voltage is 10 V/cm or less (low voltage) and the second voltage is between 12 and 20 V/cm (high voltage); and wherein the first frequency is 5 Hz or less (low frequency) and the second frequency is between 15 and 20 Hz (high frequency), and d) detecting activation of the nerve cell by measuring the changes in the signal intensity of the indicator, wherein low voltage and low frequency activation indicates a first type of cell and activation detected only at high voltage indicates a secon
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 23, 2021
    Assignee: AnaBios Corporation
    Inventors: Andrea Ghetti, Yannick Miron, Claudio Ghetti, Paul Miller
  • Patent number: 10794897
    Abstract: A drug-induced risk prediction system and associated methods are disclosed for predicting at least one of a drug-induced inotropic risk and a pro-arrhythmia risk in connection with an at least one drug, based on a select at least one contractility parameter associated with an at least one heart.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: October 6, 2020
    Assignee: AnaBios Corporation
    Inventors: Najah Elias Abi Georges, Andrea Piero Ghetti, Paul Edward Miller
  • Publication number: 20180306781
    Abstract: The present invention provides methods of identifying and distinguishing different types of nerve cells in ex vivo cell culture, the method comprising the steps of: a) culturing somato-sensory nerve cells ex vivo, b) loading the nerve cells with a calcium, sodium, or voltage-sensitive indicator or expressing a genetically encoded calcium, sodium, or voltage-sensitive indicator, c) pulsing the nerve cells with an electrical train of bipolar square waves at two different voltages and two different frequencies; wherein the first voltage is 10 V/cm or less (low voltage) and the second voltage is between 12 and 20 V/cm (high voltage); and wherein the first frequency is 5 Hz or less (low frequency) and the second frequency is between 15 and 20 Hz (high frequency), and d) detecting activation of the nerve cell by measuring the changes in the signal intensity of the indicator, wherein low voltage and low frequency activation indicates a first type of cell and activation detected only at high voltage indicates a secon
    Type: Application
    Filed: April 19, 2018
    Publication date: October 25, 2018
    Applicant: AnaBios Corporation
    Inventors: Andrea Ghetti, Yannick Miron, Claudio Ghetti, Paul Miller
  • Publication number: 20180224427
    Abstract: A drug-induced risk prediction system and associated methods are disclosed for predicting at least one of a drug-induced inotropic risk and a pro-arrhythmia risk in connection with an at least one drug, based on a select at least one contractility parameter associated with an at least one heart.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 9, 2018
    Applicant: AnaBios Corporation
    Inventors: Najah Elias Abi Georges, Andrea Piero Ghetti, Paul Edward Miller